"When considering an important decision such as cosmetic eyelid surgery (blepharoplasty), one must look for expertise in the delicate area of the eyes. David Wirta, M.D., is a board-certified ophthalmologist in Newport Beach, Orange County"

During the past decade, David Wirta, MD, Inc. conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "David Wirta, MD, Inc." are "Blepharitis" (1 trials), "Dry Eye Disease" (1 trials), "Pain" (1 trials) and "Steatoblepharon" (1 trials). Many other conditions were trialed in "David Wirta, MD, Inc." in a lesser frequency.

Most popular intervention types in "David Wirta, MD, Inc." are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Azithromycin Ophthalmic Solution, 1%" (1 trials), "Azithromycin ophthalmic solution, 1%" (1 trials), "Matching placebo" (1 trials) and "Vitrase" (1 trials). Other intervention names were less common.

The vast majority of trials in "David Wirta, MD, Inc." are 4 trials for "All" genders.

Currently, there are NaN active trials in "David Wirta, MD, Inc.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in David Wirta, MD, Inc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in David Wirta, MD, Inc., 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".